Home World News EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin World News EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR People with Intellectual Disability at Increased Risk of Cancer September 21, 2021 NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing... January 22, 2021 How My Stage 4 Esophageal Cancer Diagnosis Led Me to a... January 12, 2023 Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation May 31, 2019 Load more HOT NEWS Man Who Lost His Leg Teaches Martial Arts To Orphans Of... Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients...
